Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen

1. Kong, A.
2. Rea, D.
3. Ahmed, S.
4. Beck, J.T.
5. López, R.L.
6. Biganzoli, L.
7. Armstrong, A.C.
8. Aglietta, M.
9. Alba, E.
10. Campone, M.
11. Schmitz, S.-F.H.
12. Lefebvre, C.
13. Akimov, M.
14. Lee, S.-C.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.18632/ONCOTARGET.8974 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus